Literature DB >> 31392191

Pros and cons of different ways to address dysfunctional autophagy in Pompe disease.

Jeong-A Lim1, Naresh Kumar Meena2, Nina Raben2.   

Abstract

Autophagy is a major intracellular self-digestion process that brings cytoplasmic materials to the lysosome for degradation. Defective autophagy has been linked to a broad range of human disorders, including cancer, diabetes, neurodegeneration, autoimmunity, cardiovascular diseases, and myopathies. In Pompe disease, a severe neuromuscular disorder, disturbances in autophagic process manifest themselves as progressive accumulation of undegraded cellular debris in the diseased muscle cells. A growing body of evidence has connected this defect to the decline in muscle function and muscle resistance to the currently available treatment-enzyme replacement therapy (ERT). Both induction and inhibition of autophagy have been tested in pre-clinical studies in a mouse model of the disease. Here, we discuss strengths and weaknesses of different approaches to address autophagic dysfunction in the context of Pompe disease.

Entities:  

Keywords:  Lysosome; autophagy; enzyme replacement therapy (ERT); muscle

Year:  2019        PMID: 31392191      PMCID: PMC6642936          DOI: 10.21037/atm.2019.03.51

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


  98 in total

1.  LC3, a mammalian homologue of yeast Apg8p, is localized in autophagosome membranes after processing.

Authors:  Y Kabeya; N Mizushima; T Ueno; A Yamamoto; T Kirisako; T Noda; E Kominami; Y Ohsumi; T Yoshimori
Journal:  EMBO J       Date:  2000-11-01       Impact factor: 11.598

2.  The molecular machinery of autophagy: unanswered questions.

Authors:  Daniel J Klionsky
Journal:  J Cell Sci       Date:  2005-01-01       Impact factor: 5.285

3.  Prelysosomal and lysosomal connections between autophagy and endocytosis.

Authors:  P B Gordon; H Høyvik; P O Seglen
Journal:  Biochem J       Date:  1992-04-15       Impact factor: 3.857

4.  Effects of non-contractile inclusions on mechanical performance of skeletal muscle.

Authors:  Maarten R Drost; Reinout P Hesselink; Cees W Oomens; Ger J van der Vusse
Journal:  J Biomech       Date:  2005-05       Impact factor: 2.712

5.  Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.

Authors:  E Casado; J Gratacós; C Tolosa; J M Martínez; I Ojanguren; A Ariza; J Real; A Sanjuán; M Larrosa
Journal:  Ann Rheum Dis       Date:  2005-08-11       Impact factor: 19.103

6.  Glycogen autophagy in the liver and heart of newborn rats. The effects of glucagon, adrenalin or rapamycin.

Authors:  D J Kondomerkos; S A Kalamidas; O B Kotoulas; A C Hann
Journal:  Histol Histopathol       Date:  2005-07       Impact factor: 2.303

7.  Enzyme replacement therapy in the mouse model of Pompe disease.

Authors:  N Raben; M Danon; A L Gilbert; S Dwivedi; B Collins; B L Thurberg; R J Mattaliano; K Nagaraju; P H Plotz
Journal:  Mol Genet Metab       Date:  2003 Sep-Oct       Impact factor: 4.797

8.  An electron microscopic and biochemical study of the effects of glucagon on glycogen autophagy in the liver and heart of newborn rats.

Authors:  D J Kondomerkos; S A Kalamidas; O B Kotoulas
Journal:  Microsc Res Tech       Date:  2004-02-01       Impact factor: 2.769

Review 9.  Glycogen autophagy.

Authors:  Othon B Kotoulas; Stefanos A Kalamidas; Dimitrios J Kondomerkos
Journal:  Microsc Res Tech       Date:  2004-05-01       Impact factor: 2.769

Review 10.  Lysosomal dysfunction in muscle with special reference to glycogen storage disease type II.

Authors:  Reinout P Hesselink; Anton J M Wagenmakers; Maarten R Drost; Ger J Van der Vusse
Journal:  Biochim Biophys Acta       Date:  2003-03-20
View more
  3 in total

1.  LAMP2 Cardiomyopathy: Consequences of Impaired Autophagy in the Heart.

Authors:  Ronny Alcalai; Michael Arad; Hiroko Wakimoto; Dor Yadin; Joshua Gorham; Libin Wang; Elia Burns; Barry J Maron; William C Roberts; Tetsuo Konno; David A Conner; Antonio R Perez-Atayde; Jon G Seidman; Christine E Seidman
Journal:  J Am Heart Assoc       Date:  2021-08-28       Impact factor: 6.106

2.  CARM1 promotes gastric cancer progression by regulating TFE3 mediated autophagy enhancement through the cytoplasmic AMPK-mTOR and nuclear AMPK-CARM1-TFE3 signaling pathways.

Authors:  Suzhen Yang; Jing Zhang; Di Chen; Jiayi Cao; Ying Zheng; Yuying Han; Yirong Jin; Shuhui Wang; Ting Wang; Lin Ma; Tingting Luo; Yan Wang; Wen Qin; Lei Dong
Journal:  Cancer Cell Int       Date:  2022-03-04       Impact factor: 5.722

3.  MicroRNA-7 inhibits hepatocellular carcinoma cell invasion and metastasis by regulating Atg5-mediated autophagy.

Authors:  Jinling Yuan; Yingjia Li; Jinfeng Liao; Minji Liu; Lili Zhu; Kai Liao
Journal:  Transl Cancer Res       Date:  2020-06       Impact factor: 1.241

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.